Archimed
 
 
 
  • About Us
  • Fund
  • Support
  • Return
  • Our Companies
  • left
    • About Us
    • Our Companies
    • Sustainability & Impact
  • Fund
    • Our Investment Strategy
    • Our Investors
    • Our Funds
  • Support
    • Our Value Creation Approach
    • Our Team and Network
  • Return
    • Return to Investors
    • Return to People
    • Return to Society
  • right
    • News
    • JOIN OUR TEAM
    • Investor Portal
    • Contact

NEWS

Our Latest News

ARCHIMED Diagnostics closes its acquisition of ARK Diagnostics, a global leader in disease and drug monitoring & detection

The previous majority owner, listed South Korean specialty chemicals company, Soulbrain Holdings, retains a significant minority stake in California-based ARK.

ARCHIMED Diagnostics closes its acquisition of ARK Diagnostics, a global leader in disease and drug monitoring & detection

ARCHIMED Diagnostics closes its acquisition of ARK Diagnostics

 October

 28, 

2025

ARCHIMED’s FIM Medical becomes the leading developer and distributor of European occupational healthcare devices with its purchase of Vistec GmbH

 October

 23, 

2025

ARCHIMED buys Premium Global Dental Healthcare US Company ZimVie

 October

 20, 

2025

ARCHIMED buys Denmark’s DermaPharm A/S, a leading developer and manufacturer of skincare products

 October

 15, 

2025

ARCHIMED acquires cell line development pioneer ExcellGene to accelerate expansion into biosimilars and high-performance transfection solutions

 September

 25, 

2025

ARCHIMED acquires Rivadis, a leading player in baby and elderly skincare products

 September

 8, 

2025

1 2 3 … 16 >
368
  • ARCHIMED © 2025
  • Our Eco-Design Approach
  • Legal Notice
  • SFDR Disclosures
  • Contact Us
  • LinkedIn
  • Manage your cookies
  • .
    Go top

    Back to top